ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

H.C. Wainwright analyst Andres Maldonado initiated coverage of ImmunityBio (IBRX) with a Buy rating and $8 price target ImmunityBio is a ...

Culver City, California Saturday, March 1, 2025, 17:00 Hrs [IST] ...

ImmunityBio shares advanced 17% to $3.34 after the company said the Food and Drug Administration awarded a regenerative medicine advanced therapy designation for Anktiva and CAR-NK for the reversal of ...

ImmunityBio has entered a supply agreement and partnership with BeiGene for conducting a confirmatory Phase III ResQ201A-NSCLC trial combining tislelizumab and Anktiva to treat advanced or ...

After a momentous 2024, Culver City-based ImmunityBio Inc., the immunotherapy company founded and majority-owned by ...

Reports Q4 revenue $7.55M, consensus $9.51M. “The first quarter of 2025 has been an inflection point for the Company with multiple milestones ...

Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after-hours trading. The rally followed the company’s announcement that the U.S.

By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response.

Specifically, the company will now be able to provide this alternative to urologists for use in combination with IBRX's bladder cancer treatment, Anktiva. Typically utilized in conjunction with ...

Cytokine fusion proteins, such as ANKTIVA, represent a novel class of biologics that improve immune responses by enhancing the therapeutic potential of cytokines and promoting lymphocyte ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-c ...